FORM 4

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

	OMB Number:	3235-0287
	Estimated average burden	
-	hours per response:	0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

10b5-1(c). See Instr	uction 10.							
Name and Address of Reporting Person*     Bohnen Shane			2. Issuer Name <b>and</b> Ticker or Trading Symbol BIO-TECHNE Corp [ TECH ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
(Last) 614 MCKINLEY	(First) PLACE NE	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 08/15/2023	X	Officer (give title below)  SVP - Genera	Other (specify below)		
(Street) MINNEAPOLIS (City)	MN (State)	55413 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year) 08/17/2023	6. Indiv	ridual or Joint/Group Filing Form filed by One Rep Form filed by More tha	, ,		

# Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	Date (Month/Day/Year)	if any	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Restricted Stock Units	(1)	08/15/2023		A		4,802		(2)	(2)	Common Stock	4,802	\$0	4,802	D	
Stock Option (Right to Buy)	\$84.61	08/15/2023		A		12,924		(2)	08/15/2030	Common Stock	12,924	\$0	12,924	D	

### Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- $2.\ Vests\ in\ full\ or\ in\ part\ on\ 8/15/2026\ if\ certain\ performance\ goals\ are\ achieved\ (or\ such\ later\ date\ as\ performance\ is\ certified\ by\ the\ Administrator).$

#### Remarks:

This amendment is being filed to correct the number of restricted stock units and performance options being granted.

<u>/s/ Shane Bohnen</u> <u>12/14/2023</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.